Materials and Methods
24 48 72 HOURS AFTER INFECTION FIGURE 1 . The effect of rGM-CSF and rIFN-y on the intracellular fate of L . donovani in human monocytederived macrophages . The monocyte-derived macrophages were treated with rGM-CSF, 4 ng/ml (0) or rIFNy, 1,000 U/ml (O), or received only fresh medium (control, 0) for 72 h before infection with L. donovani. After 2 h of incubation at 37°C, the uningested parasites were removed by washing and the cultures were reincubated in fresh medium containing no rGM-CSF or rIFN-y . Coverslips were removed at 2, 24, 48 and 72 h, washed, and stained. The number of intracellular parasites was determined by microscopy. The starred circle represents the overlaps of open circle, closed circle, and diamond. Three experiments are shown; each is expressed as the mean ± SEM of three quantifications.
Results

Killing of Intracellular Leishmania Donovani by rGM-CSF or rIFN-y-activated
Monocyte-derived Macrophages. It has been shown that I-d-old human monocytes displayed effective promastigocidal activity and eradicated >90% of ingested parasites 24 h after infection (4) . However, monocyte-derived macrophages (monocytes cultured for >7 d) that could be activated to exhibit antileishmanial activity, displayed little or no leishmanicidal activity towards promastigotes of L. donovani and none towards amastigotes. Instead, these cells readily supported the replication of both parasite forms. Therefore, monocyte-derived macrophages were used as the effector cells in the present study. IFN-y has been shown to activate human mononuclear phagocytes cultured for 10-20 d to kill intracellular L. donovani (5) , with optimal results being achieved after 48-72 h of exposure . To determine if rGM-CSF can activate macrophages for antileishmanial activity and to compare the effect of pretreatment with rGM-CSF or rIFN-y on cultured monocyte-derived macrophages, rGM-CSF (4 ng/ml, the optimal dose) or rIFN-y (1,000 U/ml) was added once to 10-d-old cultures of monocytederived macrophages for 72 h before infection with the parasites. The actual replication of the parasites in rGM-CSF-and rIFN-7-treated cultures was compared with cultures receiving medium alone.
As can be seen in Fig. 1 , the uptake of parasites after 2 h was similar for each group, indicating no differential uptake of parasites among lymphokine-treated cells. In the control cultures, monocyte-derived macrophages readily supported the replication of L. donovani. However, in macrophages pretreated with rGM-CSF or rIFN-7, the growth of the parasites was inhibited.
We initiated our studies of the Leishmania-macrophage interaction using the promastigote because the hemoflagellate is the form first encountered by the phagocytic cells. The amastigote, however, to which the promastigote rapidly transforms within the phagolysosomes, is responsible for persistent tissue infec- showed a similar dose-response GM -CSF (ng/ml) curve.
tion. Therefore, amastigotes were also used to infect monocyte-derived macrophages treated with rGM-CSF or rIFN-y . The antileishmanial effect of these two lymphokines was evaluated (Table 1) . Again, there was a significant decrease of amastigotes in macrophages treated with either lymphokine, although the antileishmanial effect was more pronounced when promastigotes were used . The Fig. 2 shows the antileishmanial effect of increasing concentrations of purified rGM-CSF on monocyte-derived macrophages infected with L. donovani . Killing of L. donovani was observed at a concentration as low as 0.5 ng/ml rGM-CSF, and the optimal effect was reached at 4 ng/ml. The antileishmanial effect of rGM-CSF was entirely abolished by treatment of rGM-CSF with anti-rGM-CSF antiserum but not with anti-rIFN-y mAb (Fig. 3) . However, it is of note that no antileishmanial activity was observed in monocyte-derived macrophages treated with human recombinant macrophage-colony stimulating factor (ob- 3 . Effect of anti-rGM-CSF or anti-IFN-y antibody on the antileishmanial activity of rGM-CSF. rGM-CSF (4 ng/ml) was incubated with protein ASepharose-bound sheep anti-human rGM-CSF antiserum (40 ng/ml) or with protein A-Sepharosebound anti-IFN-y mAb (4,000 neutralizing units/ml) overnight at 4°C. The slurry was removed by centrifugation at 300 g for 10 min. 4 ng/ml rGM-CSF (p), rGM-CSF treated with anti-rGM-CSF antibody (0), or rGM-CSF with anti-IFN-y antibody (/) were added to cultured macrophages 72 h before infection with L. donovani . The percentage of parasites killed was assessed 48 h after infection and calculated as described in Table I . Three experiments are shown; each is expressed as the mean t SEM of three quantifications.
tained from Genetics Institute), another cytokine produced by using the same COS cell expression system as rGM-CSF (data not shown) .
It has been reported that the macrophage-activating activity of IFN-7 is dependent on the presence of small amounts of bacterial LPS as a second signal (21, 23, 24) . Therefore, to assess whether exogenous LPS is required for antileishmanial activity of rGM-CSF or IFN-1', human monocyte-derived macrophages were processed and cultured under stringent LPS-free conditions as described in Materials and Methods. rGM-CSF and IFN-7, both free of detectable amounts of LPS, were used to activate monocyte-derived macrophages with and without the addition of 10 ng or 50 ng/ml of LPS. As illustrated in Table II , the antileishmanial activity of both rGM-CSF and IFN -'y was found not to be affected by the addition of either 10 ng or 50 ng of LPS. Furthermore, both lymphokines were able to function in a LPS-free environment since culture medium removed at the termination of the experiment (72 h after infection) contained no detectable amount of LPS (<0.01 ng/ml). In addition, LPS alone showed no antileishmanial activity .
Time Course of rGM-CSF. The antileishmanial effect of pretreating cultured monocyte-derived macrophages for different times with 4 ng/ml rGM-CSF or with 1,000 U/ml rIFN-7 was measured 48 h after infection (Fig . 4 ) . Already at 6 h of pretreatment, activation was seen with rGM-CSF, whereas no effect was seen with rIFN-.
y . Optimal activation with rGM-CSF occurred at 36 h of pretreatment with rGM-CSF whereas activation by rIFN-y was maximal only after 72 h of preincubation . The latter is in agreement with previous reports by Murray and Cartelli (4) . These studies clearly demonstrate that rGM-CSF activates cultured human monocytes quicker than rIFN-gamma .
Are the Antileishmanial Effects of rGM-CSF and rIFN-y Additive? Our experiments show that even when optimal concentrations of rIFN-y or rGM-CSF are used, all intracellular parasites are not eradicated . Some residual parasites remain insensitive to the treatment of macrophages with either lymphokine . These observations bring up the question : can the residual parasite population be killed by treating monocyte-derived macrophages with a combination of rGM-CSF and rIFN-y, especially in view of the reports that IFN-y but not GM-CSF induced Failure of LPS to Alter Macrophage Antileishmanial Activity Induced by GM-CSF and IFN-y * Monocyte-derived macrophges were treated as indicated above for 72 h. The cells were then infected with promastigotes of L. donovani for 2 h. Coverslips were removed at 2 h and 48 h after infection. $ The number of intracellular parasites per 100 macrophages at 2 h and at 48 h after infection was determined as described in Table I . All the experiments within each group were analyzed by the two-way analysis of variance . No statistical significance was found to reject the null hypothesis of equal activity of activated samples untreated or further treated with LPS. Therefore, it is concluded that no significant enhancement of activity is detected by adding LPS to GM-CSF or IFN-y-treated cultures .
WEISER ET AL . 5 . Antileishmanial activity of combined treatment of monocyte-derived macrophages with rGM-CSF and rIFN-y . Cells were treated with medium alone (0), 200 U/ml rIFN-y (A), 0.5 ng/ml rGM-CSF (A), 0.5 ng rGM-CSF and 200 U/ml rIFN-y (*), 1,000 U/ml rIFN-y (0), 4 ng/ml rGM-CSF (9), or 4 ng/ml rGM-CSF and 1,000 U/ml rIFN-y (*) for 72 h before infection with L. donovani. Number of intracellular parasites were was 2, 24, 48, and 72 h after infection. The data represent the mean of three experiments.
human macrophages to secrete H202 (25) and that promastigotes of L. donovani were found to be exquisitely susceptible to H202 (4). Results of three separate experiments using different concentrations of rGM-CSF and rIFN-y concomitantly are shown in Fig. 5 . As can be seen, pretreatment of monocyte-derived macrophages with a combination of rGM-CSF and rIFN-y at suboptimal doses (0 .5 ng/ml and 200 U/ml) results in an additive killing effect of L. donovani, when compared with pretreatment with either lymphokine alone. However, pretreatment with rGM-CSF and rIFN-y at optimal doses (4 ng/ml and 1,000 U/ml) showed no significant enhanced killing of parasites.
Discussion
These results demonstrate that human rGM-CSF activates cultured human monocyte-derived macrophages to exhibit antileishmanial activity towards both promastigotes and amastigotes of L. donovani . The activation of the macrophages by rGM-CSF is maximal after 36 h of incubation, whereas, activation by rIFN-y is maximal at 72 h . The activation of intracellular killing by rGM-CSF or by IFN-y does not require LPS as a second stimulus ; the antileishmanial effect of both lymphokines containing no detectable LPS is not potentiated by the addition of LPS. Furthermore, treatment with LPS alone showed no effect on the intracellular killing of L. donovani . In this context, Grabstein et al . (21) found that the capacity of GM-CSF to activate macrophages to lyse A375 target cells was independent of stimulation with suboptimal amounts of LPS, but the capacity of IFN-y to activate macrophages, on either hand, required the addition of suboptimal amounts of LPS to achieve lysis of the same cells. Furthermore, LPS alone (1 ng or 10 ng/ml) was able to induce nonspecific tumoricidal activity .
Other studies have also addressed the process of macrophage activation by GM-CSF . In regard to antileishmanial activity, it was demonstrated that conditioned medium from mouse spleen cells containing GM-CSF activity was able to enhance ingestion and killing of Leishmania tropica by mouse macrophages (26) ; however, in this study homogeneity of GM-CSF could not be demonstrated in order to exclude the action of IFN-y . On the other hand, Ralph et al . (27) also using conditioned medium from mouse spleen cells reported that GM-CSF obtained by gel chromatography of conditioned medium does not play a role in the induction of tumoricidal and microbicidal activity of mouse macrophages. The reason for the latter finding could be the presence of an inhibitor of GM-CSF in the conditioned medium or insufficient pretreatment time of macrophages, or that mouse GM-CSF indeed lacks macrophage-activating activity . The antimicrobial activity of GM-CSF has recently been extended to Trypanosoma cruzi and Salmonella typhimurium (13, 15) . In these studies, treatment of rGM-CSF was found to activate human peripheral blood monocytes and macrophages as well as mouse peritoneal macrophages for the inhibition of intracellular replication of trypomastigotes of T. cruzi (13, 15) , and daily GM-CSF therapy significantly increased the survival of mice challenged with a lethal dose of S. typhimurium (13) .
Recently, the contribution of highly active NK cells, which are present in small numbers in monocyte preparations, to extracellular cytotoxicity has gained increasing attention (28) . This is important because target cells, including the A375 cell line, previously thought to be exclusively sensitive to monocyte killing were found to be highly susceptible to NK cell killing. We have circumvented this problem by assessing intracellular killing associated exclusively with macrophages .
It is not yet clear how GM-CSF induces antileishmanial activity in macrophages upon infection with leishmania . Human mononuclear phagocytes have been shown to use both oxygen-dependent and -independent mechanisms to kill ingested Leishmania (4). In the oxygen-dependent mechanism, H202 has been identified as the key leishmanicidal oxygen intermediate (29, 30) . Whereas IFNy has the capability to induce mononuclear phagocytes to use both oxygendependent and -independent mechanisms to achieve leishmanicidal activity (4), GM-CSF, on the other hand, did not enhance H202 release from macrophages upon triggering with PMA (25) . However, it is not entirely impossible that macrophages treated with GM-CSF are rendered more susceptible to be triggered for oxidative burst during parasite entry than untreated macrophages, since oxidative burst could also be readily triggered by the entry of promastigotes of L. donovani (4). Alternatively, GM-CSF might operate through an oxygenindependent mechanism to achieve antileishmanial activity . In a recent report by Passwell et al. (31) , mAb to IFN-y, which abrogated the increase in production of H202 induced by supernatants from mitogen-stimulated human peripheral blood mononuclear cells, resulted in only partial inhibition of leishmanicidal capacity of these lymphokines on human monocytes. It is also possible that GM-CSF activates macrophages to release TNF and that some of the biological effects of GM-CSF might be amplified through the release of TNF. By Nothern blot analysis, rGM-CSF has recently been shown to induce expression of the TNF gene in U937 cells and in normal human monocytes (32) . Furthermore, rGM-CSF, but not rIFN-y was found to induce human monocyte-derived macrophages to express mRNA for TNF-a (33) . Also, rTNF has been demonstrated to inhibit intracellular multiplication of trypomastigotes of T. cruzi in murine macrophages (10) . The role of TNF in the antileishmanial action is currently being investigated.
The experiments reported here show that homogeneous human rGM-CSF devoid of other lymphokines induces intracellular killing of L. donovani by monocyte-derived macrophages. The role of GM-CSF in vivo as a macrophageactivating factor and its functional relationship to IFN-y remains to be determined. GM-CSF might be produced rapidly after an antigenic stimulus, or exposure to endotoxin or IL-1, because injection of various Salmonella antigens or endotoxin into mice caused a 50-100-fold increase of serum CSF levels, maximal at 3-9 h (34), and administration of 100 ng of human IL-1 to mice resulted in the appearance of high serum titers of CSF at 3 and 6 h (35). Therefore, GM-CSF might be important whenever early activation of macrophages is necessary, whereas IFN-y might function as a long-term macrophageactivating factor. Since simultaneous administration of suboptimal doses of rGM-CSF and rIFN-y to macrophages induces an additive antileishmanial effect, it may be beneficial to combine these two lymphokines therapeutically to promote hematopoietic cell proliferation and to activate macrophages.
Summary
Recombinant granulocyte/macrophage colony-stimulating factor (rGM-CSF) obtained from cloned complementary Mo cell DNA and expressed in COS-1 cells activates cultured peripheral blood monocyte-derived macrophages in vitro to become cytotoxic for intracellular L. donovani . The antileishmanial effect of rGM-CSF, which can be completely neutralized by anti-rGM-CSF antiserum, is maximal after 36 h preincubation with the cultured macrophages, compared with that of rIFN-gamma, which reaches its maximum at 72 h of preincubation. The antileishmanial effect of GM-CSF as well as IFN-y is independent of detectable amounts of LPS and is not augmented by the addition of 10 or 50 ng/ml of LPS. Simultaneous administration of suboptimal doses of rGM-CSF and rIFN-y to monocyte-derived macrophages results in greater antileishmanial activity by these cells than administration of either lymphokine alone, although no enhancement of antileishmanial activity is observed when optimal doses of these two lymphokines are applied together .
